BRCA1 and BRCA2 germline mutations in 85 Iranian breast cancer patients

被引:16
作者
Keshavarzi, Fatemeh [2 ]
Javadi, Gholam Reza [3 ]
Zeinali, Sirous [1 ,4 ]
机构
[1] Kawsar Human Genet Res Ctr, Med Genet Lab Dr Zeinali, Tehran, Iran
[2] Islamic Azad Univ, Sanandaj Branch, Dept Biol, Sanandaj, Iran
[3] Islamic Azad Univ, Sci & Res Branch, Dept Biol, Tehran, Iran
[4] Inst Pasteur, Tehran, Iran
关键词
BRCA1; gene; BRCA2; Genetic polymorphisms; Breast cancer; OVARIAN-CANCER; HEREDITARY BREAST; SEQUENCE VARIANTS; RISK; GENE; FAMILIES; POLYMORPHISMS; WOMEN; SUSCEPTIBILITY; EPIDEMIOLOGY;
D O I
10.1007/s10689-011-9477-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer is the most common cancer in Iranian women (Mousavi et al in Asian Pac J Cancer Prev 9(2):275-278, 2008). Genetic predisposition accounts for 15% of all breast cancers and germline mutations in breast cancer susceptibility genes, BRCA1 and BRCA2 are responsible for a substantial proportion of high-risk breast and breast/ovarian cancer families (Collaborative Group on Hormonal Factors in Breast Cancer in Lancet 350:1047-1059, 1997; Lee et al in Int Nurs Rev 55:355-359, 2008; Hulka and Stark in Lancet 346:883-887, 1995; Kelsey in Epidemiol Rev 15:256-263, 1993; Tischer et al in J Biol Chem 266:11947-11954, 1991; Newman et al in: Proc Natl Acad Sci USA 85:3044-3048, 1988). Therefore, the aim of this study was to investigate mutations of BRCA1/2 in high risk Iranian families. We screened 85 patients who met our minimal criteria. The entire coding sequences and each intron/exon boundaries of BRCA1/2 genes were screened by direct sequencing. In the present study, we could detect the novel following mutations: p.Glu1735 p.Gly1140Ser, p.Ile26Val, p.Leu1418X, p.Glu23Gln, p.Leu3X, p.Asn1403His, p.Lys581X, p.Pro938Arg, p.Thr77Arg, p.Arg7Cys, p.Ser177Thr, IVS7+83(TT), IVS8-70(-CATT), IVS2+9(-GC), IVS1-20(-GA), IVS1-8(-AG), IVS2+24(AG), IVS5-8 (A-G), IVS2(35-39)TTcctatGAT in BRCA1 and p.Glu1391Gly, 1994_1995 (Ins A), IVS6-70-T > G in BRCA2. In agreement with findings in other populations, we found that family history is a good predictor of being a mutation carrier. Five pathogenic BRCA1 mutations and one pathogenic BRCA2 mutation were detected in 85 index cases.
引用
收藏
页码:57 / 67
页数:11
相关论文
共 51 条
[1]   Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation [J].
Abkevich, V ;
Zharkikh, A ;
Deffenbaugh, AM ;
Frank, D ;
Chen, Y ;
Shattuck, D ;
Skolnick, MH ;
Gutin, A ;
Tavtigian, SV .
JOURNAL OF MEDICAL GENETICS, 2004, 41 (07) :492-507
[2]   Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies [J].
Antoniou, A ;
Pharoah, PDP ;
Narod, S ;
Risch, HA ;
Eyfjord, JE ;
Hopper, JL ;
Loman, N ;
Olsson, H ;
Johannsson, O ;
Borg, Å ;
Pasini, B ;
Radice, P ;
Manoukian, S ;
Eccles, DM ;
Tang, N ;
Olah, E ;
Anton-Culver, H ;
Warner, E ;
Lubinski, J ;
Gronwald, J ;
Gorski, B ;
Tulinius, H ;
Thorlacius, S ;
Eerola, H ;
Nevanlinna, H ;
Syrjäkoski, K ;
Kallioniemi, OP ;
Thompson, D ;
Evans, C ;
Peto, J ;
Lalloo, F ;
Evans, DG ;
Easton, DF .
AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (05) :1117-1130
[3]   Characterization of a novel large deletion and single point mutations in the BRCA1 gene in a Greek cohort of families with suspected hereditary breast cancer -: art. no. 61 [J].
Belogianni, I ;
Apessos, A ;
Mihalatos, M ;
Razi, E ;
Labropoulos, S ;
Petounis, A ;
Gaki, V ;
Keramopoulos, A ;
Pandis, N ;
Kyriacou, K ;
Hadjisavvas, A ;
Kosmidis, P ;
Yannoukakos, D ;
Nasioulas, G .
BMC CANCER, 2004, 4 (1)
[4]  
Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0
[5]   AT-tributable risks? [J].
Bishop, DT ;
Hopper, J .
NATURE GENETICS, 1997, 15 (03) :226-226
[6]   Contribution of BRCAI and BRCA2 germ-line mutations to the incidence of breast cancer in young women:: Results from a prospective population-based study in France [J].
Bonadona, V ;
Sinilnikova, OM ;
Chopin, S ;
Antoniou, AC ;
Mignotte, H ;
Mathevet, P ;
Brémond, A ;
Martin, A ;
Bobin, JY ;
Romestaing, P ;
Raudrant, D ;
Rudigoz, RC ;
Léoné, M ;
Chauvin, F ;
Easton, DF ;
Lenoir, GM ;
Lasset, C .
GENES CHROMOSOMES & CANCER, 2005, 43 (04) :404-413
[7]   BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models [J].
Capalbo, C. ;
Ricevuto, E. ;
Vestri, A. ;
Ristori, E. ;
Sidoni, T. ;
Buffone, O. ;
Adamo, B. ;
Cortesi, E. ;
Marchetti, P. ;
Scambia, G. ;
Tomao, S. ;
Rinaldi, C. ;
Zani, M. ;
Ferraro, S. ;
Frati, L. ;
Screpanti, I. ;
Gulino, A. ;
Giannini, G. .
ANNALS OF ONCOLOGY, 2006, 17 :VII34-VII40
[8]   MUTATIONS IN THE BRCA1 GENE IN FAMILIES WITH EARLY-ONSET BREAST AND OVARIAN-CANCER [J].
CASTILLA, LH ;
COUCH, FJ ;
ERDOS, MR ;
HOSKINS, KF ;
CALZONE, K ;
GARBER, JE ;
BOYD, J ;
LUBIN, MB ;
DESHANO, ML ;
BRODY, LC ;
COLLINS, FS ;
WEBER, BL .
NATURE GENETICS, 1994, 8 (04) :387-391
[9]   Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients [J].
Choi, DH ;
Lee, NH ;
Bale, AE ;
Carter, D ;
Haffty, BG .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) :1638-1645
[10]   Differentiating pathogenic mutations from polymorphic alterations in the splice sites of BRCA1 and BRCA2 [J].
Claes, K ;
Poppe, B ;
Machackova, E ;
Coene, I ;
Foretova, L ;
De Paepe, A ;
Messiaen, L .
GENES CHROMOSOMES & CANCER, 2003, 37 (03) :314-320